Glaukos Corp (NYSE:GKOS)
$ 127.45 1.18 (0.93%) Market Cap: 7.00 Bil Enterprise Value: 6.83 Bil PE Ratio: 0 PB Ratio: 10.51 GF Score: 64/100

Glaukos Corp at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2022 / 10:15PM GMT
Release Date Price: $53.34 (+10.78%)
K. Gong
JPMorgan Chase & Co, Research Division - Associate

Okay. Good afternoon, everyone. Welcome to the final session of Tuesday here at the JPMorgan Healthcare Conference. My name is Allen Gong. I'm on the Medical Supplies and Devices team, and I'm very excited to be introducing the management team of Glaukos today. Starting with prepared remarks, we'll be Tom Burns, President and CEO; and then during the Q&A, we'll be joined by COO, Chris Calcaterra; and CFO, Joe Gilliam.

I will be running the Q&A session to follow prepared remarks so if you have any questions at all, feel free to shoot them over to me through e-mail, through Bloomberg or through the online portal itself.

With that, Tom, it's all you.

Thomas William Burns
Glaukos Corporation - Chairman, CEO & President

Okay. Thank you, Allen, and good afternoon. I'm delighted to be able to present on Glaukos Corporation today. We founded Glaukos to transform glaucoma therapy, but as you know, our aspirations have always been far higher. And today, we seek to transform

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot